Heron Therapeutics (HRTX) Non Operating Income (2014 - 2026)

Heron Therapeutics has reported Non Operating Income for 13 years, with the latest figure at -$3.3 million in Q1 2026.

• For the quarter ending Q1 2026, Non Operating Income fell 544.7% year-over-year to -$3.3 million; the trailing twelve-month figure through Mar 2026 stood at -$1.5 million (up 13.84% YoY), and the FY2025 full-year result was $1.3 million, up 211.4% from the prior year.
• Non Operating Income for Q1 2026 stood at -$3.3 million, down from $4.7 million in the prior quarter.
• The five-year high for Non Operating Income was $4.7 million in Q4 2025, with the low at -$6.9 million in Q2 2022.
• Historically, Non Operating Income has averaged -$471687.5 across 5 years, with a median of -$234500.0 in 2023.
• Annual changes were most pronounced in 2022 — Non Operating Income sank 1156.59% — and 2024, when it jumped 455.25%.
• Heron Therapeutics' Non Operating Income stood at $1.3 million in 2022, then plunged by 105.98% to -$79000.0 in 2023, then surged by 2596.2% to $2.0 million in 2024, then soared by 136.56% to $4.7 million in 2025, then slumped by 171.73% to -$3.3 million in 2026.
• The last three Non Operating Income figures came in at -$3.3 million (Q1 2026), $4.7 million (Q4 2025), and -$2.1 million (Q3 2025), per Business Quant data.